DEPARTMENTS | DIRECTORY | ADVANCED SEARCH | SCHOOL HOME
School Home NYU School of Medicine

irb
 Today is Saturday, September 6th 2008
 
Guidance Documents
Decision Charts -
Human Subject Regulations Decision Charts
NYU SoM IRB Guidelines for Writing a Research Protocol
Guidance of Required Elements of a Protocol
Guidance on Determining Human Subjects Research
Guidance on Submitting a New Application
Guidance on Using an FDA Regulated Product
Guidance for the Investigator as a Sponsor
Guidance for Data Monitoring Plans
Guidance for Emergency Use of an IND
Guidance for Emergency Use of an IND-IDE
Guidelines for Research in Pregnant Women, Human Fetuses and Neonates
Guidance on Research with Prisoners
Guidelines for Involving Children in Research
Guidance for Cognitively Impaired
Guidance for Students and Employees in Research
Guidelines for Recruitment of Research Subjects
Guidelines for Advertisements for Research Subjects
Guidance on Genetic Research
Guidelines on Protocol Development for Genetic Research
Guidance on the Consent Process and Documentation
Guidelines of Requests for Waiver of Consent
Guidance on Assent of A Minor
Guidance for Non-English Speaking Subjects
Guidance on Verbal Consent
Guidance on Waiver of Parental Permission
Guidelines for Amending a Protocol
Guidance on Continuing Review and Final Closures
Essential Documents
Guidelines to Investigator Responsibilities
Letter for Sponsors - Reportable Events Policy
Guidance for Reportable Events and Reporting Unanticipated Problems
Reviews Preparatory to Research

Research Data Compilations

How many copies do I submit?
 

Events and Information that Require Prompt Reporting to the IRB

You can also download this page in PDF | MS Word format.

Note: Submit a narrative summary of all adverse events, (previously reported or not, serious or not), and submit routine, periodic reports (e.g. DMC reports that indicate no changes, sponsor annual progress reports) to the IRB at Continuing Review (renewal).

WHEN REPORTING EVENTS:

Reportable information should always be reported by the PI directly to the IRB within 5 working days from when the PI learns of the event or new information.  

  • Use the IRB Reportable Events Form found at www.med.nyu.edu/irb
  • Reporting an unanticipated problem involving risks to participants or others (UAP):
    • If PI is the only monitoring entity:
      Items in section I below must be reported immediately.  
      Items in section II below should be reported directly to the IRB within 5 working days
    • If there is a monitoring entity in addition to, or other than, the PI: Report to the IRB using this form within 10 working days from receiving an assessment from monitoring entity. Only when an event has been assessed by the monitoring entity to be a UAP should the PI report it to the IRB.

I. UNANTICIPATED PROBLEMS INVOLVING RISKS TO PARTICIPANTS OR OTHERS (UAPS)

UAPs are events (including internal or external events, deaths*, life-threatening experiences*, injuries, breaches of confidentiality, or other problems) that occur any time during or after the research study, which in the opinion of the Monitoring Entity or the PI are:

  1. a. Unanticipated - not in the consent form, investigator brochure, protocol, package insert, or label; or unanticipated in its frequency, severity, or specificity,
    AND
  2. Related to the research procedures - caused by, or probably caused by research activity, or, if a device is involved, probably caused by, or associated with the device,
    AND
  3. Harmful - caused harm to participants or others, or placed them at increased risk of harm

In other words, to qualify as a UAP, an event must be Unanticipated AND Related AND Harmful.

*Unanticipated deaths or life-threatening experiences related to the research (at NYUMC or when NYUMC is the coordinating institution in a multi-site study) must be reported within 5 working days from when the research team learns of the event.

II. OTHER REPORTABLE EVENTS AND INFORMATION (other than UAPS)

  1. New Information indicating a change to the risks or potential benefits of the research, in terms of severity or frequency. [e.g., Analysis indicates lower-than-expected response rate or a more severe or frequent side effect; Other research finds arm of study has no therapeutic value; FDA labeling change or withdrawal from market]  
  2. Protocol Deviation or Violation. Only if:
    • Intended to eliminate apparent immediate hazard to a research participant, or
    • Harmful (caused harm to participants or others, or placed them at increased risk of harm, or
    • Possible serious or continued noncompliance
  3. Complaint
    • unresolved by the research team, or
    • that indicates increased or unexpected risks.
  4. Incarceration when in the opinion of the PIit is in the best interest of the participant to remain on the study.
  5. Unanticipated adverse device effect. New information about the effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence, or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.
 

IRB Resources
HRPP Accreditation Tutorial
IRB CITI Tutorials
Decision Charts -
Human Subject Regulations Decision Charts
IRB Newsletter
IRB Course Calendar
Policies and Procedures
HELP Downloading Forms
Lay Glossary
Useful Web Links
Sponsored Programs Administration (SPA)
Office of Clinical Trials (OCT)
Email a Suggestion or Comment to the IRB
Contact the IRB
GCRC Web Page
Instructions for Research Conducted at Bellevue
Printer-Friendly Version
Email this to a friend


Dept. Home | FAQs | IRB Forms | HIPAA Forms | Other Forms | Consent Templates | Info Sheets | Tool Kit | Schedule | Categories of Review | Policies | Glossary | Helpful Web Links | FWA | Contact